# US 10,500,216 B2 · Optimizing mifepristone absorption

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,500,216 B2
- Document ID: US10500216B2
- Status: Granted
- Kind: B2
- Application number: 13/677,465
- Filed: 2012-11-15
- Published: 2013-05-23
- Granted: 2019-12-10
- Earliest claimed: 2011-11-18
- Assignees: Corcept Therapeutics, Inc.
- Applicants: Corcept Therapeutics, Inc.
- Inventors: Joe Belanoff; Robert Roe; Caroline Loewy
- Web page: https://patentgrep.com/patent/US10500216B2

## CPC

- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 31/567: substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides a method for altering the pharmacokinetics of mifepristone upon oral administration. Mifepristone absorption into the blood is increased upon administration with meals. The method of the invention can benefit patients suffering from conditions including psychiatric illnesses and hormonal disorders.

## Claims

### Claim 1

A method of improving absorption of mifepristone in a patient suffering from Cushing's Syndrome, comprising administering to the patient for at least 7 days an oral dose of mifepristone of 1200 mg per day within 30 minutes after consuming a meal, such that the pharmacokinetics of mifepristone are altered by increasing the maximum plasma concentration (Cmax) and increasing the area under the curve (AUC) as compared to the Cmax and AUC that would result from administering mifepristone without food in the fasted state in the absence of the meal, said increase in AUC being at least 44% and thereby increasing mifepristone absorption in the patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient is a male.

### Claim 3 (depends on 1)

The method of claim 1, wherein the mifepristone is administered as a single dose.

### Claim 4 (depends on 1)

The method of claim 1 where the patient suffers from Cushing's disease.